SCHEMBL1318082

SCHEMBL1318082

CCOc1ccc(N)c(C(=O)O)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
MAPK8 P45983 1/20 0.42
ALDH1A1 P00352 5/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 4/20 0.38
HSD17B10 Q99714 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 2/20 0.38
CYP1A2 P05177 1/20 0.38
TSHR P16473 1/20 0.38
USP2 O75604 1/20 0.38
CREBBP Q92793 1/20 0.37
GCK P35557 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
APOBEC3G Q9HC16 1/20 0.37
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11907402 0.84 BTK (0.48) MAPTMAPK8ALDH1A1NPC1RAB9A
SCHEMBL1315299 0.84 MAPK8 (0.43) MAPTMAPK8ALDH1A1NPC1RAB9A
SCHEMBL3058519 0.81 TDP1 (0.51) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL11909627 0.79 MAPT (0.40) MAPTALDH1A1NPC1RAB9AMAPK1
SCHEMBL1680784 0.77 MAPT (0.50) MAPTMAPK8ALDH1A1NPC1RAB9A
SCHEMBL1317366 0.75 MAOA (0.48) MAPTALDH1A1NPC1RAB9AMAPK1
SCHEMBL2955940 0.74 ALDH1A1 (0.42) MAPTMAPK8ALDH1A1NPC1RAB9A
SCHEMBL11909249 0.73 FFAR1 (0.47) MAPTALDH1A1NPC1RAB9AKDM4E
SCHEMBL11908142 0.73 DHODH (0.49) MAPTALDH1A1NPC1RAB9AKDM4E
SCHEMBL1315672 0.73 PRKAB2 (0.40) MAPTALDH1A1NPC1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2375899-B1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES ARRAY BIOPHARMA INC (US) 2015-02-25 EP disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-11-10 US disclosed
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF NOS1, NOS2, ASS1 MAPT 2109/4885MAPK8 3189/4885ALDH1A1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.